次世代バイオ製造市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

次世代バイオ製造市場は、2023年に191億米ドルと評価され、2024年には206億9,000万米ドルに達すると予測され、CAGR 9.02％で成長し、2030年には349億7,000万米ドルに達すると予測されています。

次世代バイオ製造は、医薬品、バイオ燃料、バイオマテリアルなどの生物学的製品を、より効率的で持続可能かつスケーラブルに生産することを可能にする高度なバイオテクノロジー・プロセスを指します。この画期的なアプローチは、遺伝子工学、合成生物学、高度な分析を統合し、生産効率を最適化し、環境への影響を低減し、生体分子の治療可能性を高める。この技術の必要性は、個別化医薬品に対する需要の高まり、持続可能性への関心の高まり、費用対効果の高い生産技術の必要性から生じています。主な用途には、精密医療、グリーンケミストリー、人工生体材料などがあり、最終用途分野はヘルスケア、農業、エネルギーから消費財まで多岐にわたる。市場を牽引しているのは、オミックス技術における技術進歩、革新的な治療法を必要とする慢性疾患の負担増、バイオベース製品を促進する支持的な規制枠組みです。生物製剤、バイオシミラー、バイオ治療薬の開発には大きなビジネスチャンスがあり、特に精密発酵と無細胞合成生物学が有望視されています。しかし、この市場は、高額な初期資本投資、複雑な規制状況、遺伝子組み換えに対する倫理的懸念といった課題に直面しています。これらを克服するために、企業はプロセスの最適化のための研究開発に投資し、コンプライアンス・プロセスを合理化するために規制機関と協力することができます。イノベーションは、プロセス設計のための計算モデリング、製造における適応制御システム、新規の生体触媒やバイオリアクターの開発で花開くことができます。これらの分野は、コスト効率と製品収率を大幅に改善する可能性を秘めています。市場の洞察によれば、酵素工学、個別化医療、代謝経路の改変をターゲットとした戦略的提携や買収が極めて重要です。こうした取り組みは、製品ポートフォリオを多様化するだけでなく、新興市場への参入を促進します。また、AIや機械学習を活用してバイオ製造プロセスをデジタル化し、オペレーションや予知保全を強化する傾向も強まっており、これらは急速に進化する業界の情勢において競争優位を獲得するための中心的な要素となっています。

市場力学：急速に進化する次世代バイオ製造市場の主要市場インサイトを公開

次世代バイオ製造市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響についてより明確に理解することができます。

• 市場促進要因
  • バイオ医薬品と遺伝子治療に対する需要の高まり
  • バイオ製造の柔軟性と拡張性を高めるニーズの高まり
  • プロセスの自動化と連続製造の採用
• 市場抑制要因
  • 次世代バイオ製造の高コスト
• 市場機会
  • 次世代バイオ製造の進歩
  • 次世代バイオ製造への多額の投資
• 市場の課題
  • 次世代バイオ製造における技術的課題

ポーターのファイブフォース：次世代バイオ製造市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、次世代バイオ製造市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：次世代バイオ製造市場における外部からの影響の把握

外部マクロ環境要因は、次世代バイオ製造市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析次世代バイオ製造市場における競合情勢の把握

次世代バイオ製造市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス次世代バイオ製造市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、次世代バイオ製造市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨次世代バイオ製造市場における成功への道筋を描く

次世代バイオ製造市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • バイオ医薬品と遺伝子治療の需要増加
    • バイオ製造の柔軟性と拡張性を高める必要性が高まる
    • プロセス自動化と連続製造の導入
  • 抑制要因
    • 次世代バイオ製造のコストが高い
  • 機会
    • 次世代バイオ製造の進歩
    • 次世代バイオ製造への多額の投資
  • 課題
    • 次世代バイオ製造における技術的な課題
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 次世代バイオ製造市場：タイプ別

• 継続的な上流バイオ製造
• 下流バイオ製造
• 使い捨て上流バイオ製造

第7章 次世代バイオ製造市場：用途別

• ホルモン
• モノクローナル抗体
• 組み換えタンパク質
• ワクチン

第8章 次世代バイオ製造市場：エンドユーザー別

• バイオ医薬品企業
• 契約製造組織
• 調査機関

第9章 南北アメリカの次世代バイオ製造市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の次世代バイオ製造市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの次世代バイオ製造市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Agilent Technologies, Inc.
• Applikon Biotechnology BV
• bbi-biotech GmbH
• Biofluidica, Inc.
• Danaher Corporation
• Eppendorf AG
• ESCO Group
• Eurofins Scientific SE
• GEA Group AG
• GENEWIZ, Inc. by Azenta Life Sciences
• Hamilton Company
• Illumina, Inc.
• Macrogen Inc.
• Merck KGaA
• Oxford Nanopore Technologies plc
• PBS Biotech, Inc.
• PerkinElmer Inc.
• QIAGEN N.V.
• Sartorius AG
• Shanghai Bailun Biotechnology Co., Ltd.
• Solaris Biotechnology Srl by DONALDSON ITALIA S.R.L.
• Takara Bio Inc.
• Thermo Fisher Scientific Inc.
• ZETA GmbH
• Zymo Research Corporation

LIST OF FIGURES

• FIGURE 1. NEXT-GENERATION BIOMANUFACTURING MARKET RESEARCH PROCESS
• FIGURE 2. NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. NEXT-GENERATION BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. NEXT-GENERATION BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEXT-GENERATION BIOMANUFACTURING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEXT-GENERATION BIOMANUFACTURING MARKET DYNAMICS
• TABLE 7. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTINUOUS UPSTREAM BIOMANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY DOWNSTREAM BIOMANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY SINGLE-USE UPSTREAM BIOMANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY HORMONES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. CANADA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 32. CANADA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. CHINA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. CHINA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. INDIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. INDIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. ITALY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. ITALY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. POLAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 116. POLAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. QATAR NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. QATAR NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM NEXT-GENERATION BIOMANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. NEXT-GENERATION BIOMANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. NEXT-GENERATION BIOMANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

The Next-Generation Biomanufacturing Market was valued at USD 19.10 billion in 2023, expected to reach USD 20.69 billion in 2024, and is projected to grow at a CAGR of 9.02%, to USD 34.97 billion by 2030.

Next-generation biomanufacturing refers to advanced biotechnological processes enabling more efficient, sustainable, and scalable production of biological products such as pharmaceuticals, biofuels, and biomaterials. This revolutionary approach integrates genetic engineering, synthetic biology, and advanced analytics to optimize production efficiency, reduce environmental impact, and enhance the therapeutic potential of biomolecules. The necessity of this technology stems from rising demands for personalized medicines, increasing focus on sustainability, and the need for cost-effective production techniques. Key applications include precision medicine, green chemistry, and engineered living materials, while end-use sectors range from healthcare, agriculture, and energy to consumer goods. The market is driven by technological advancements in omics technologies, the increasing burden of chronic diseases requiring innovative therapies, and supportive regulatory frameworks promoting bio-based products. Significant opportunities lie in the development of biologics, biosimilars, and biotherapeutics, with precision fermentation and cell-free synthetic biology holding particular promise. However, the market faces challenges like high initial capital investments, complex regulatory landscapes, and ethical concerns over genetic modification. To overcome these, companies can invest in R&D for process optimization and collaborate with regulatory bodies to streamline compliance processes. Innovation can flourish in computational modeling for process design, adaptive control systems in manufacturing, and development of novel biocatalysts or bioreactors. These areas hold potential to significantly improve cost efficiencies and product yields. Market insights indicate that strategic partnerships and acquisitions targeting enzyme engineering, personalized medicine, and metabolic pathway modifications are crucial. These efforts will not only diversify product portfolios but will also facilitate entry into emerging markets. There is also a growing trend towards digitizing biomanufacturing processes, leveraging AI and machine learning to enhance operations and predictive maintenance, which are central to achieving a competitive edge in this rapidly evolving industry landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Biomanufacturing Market

The Next-Generation Biomanufacturing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing demand for biopharmaceuticals and gene therapies
  • Rising need to enhance flexibility and scalability of biomanufacturing
  • Adoption of process automation and continuous manufacturing
• Market Restraints
  • High cost of next-generation biomanufacturing
• Market Opportunities
  • Advancements in next-generation biomanufacturing
  • Significant investments in next-generation biomanufacturing
• Market Challenges
  • Technical challenges in next-generation biomanufacturing

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Biomanufacturing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Biomanufacturing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Biomanufacturing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Biomanufacturing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Biomanufacturing Market

A detailed market share analysis in the Next-Generation Biomanufacturing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Biomanufacturing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Biomanufacturing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next-Generation Biomanufacturing Market

A strategic analysis of the Next-Generation Biomanufacturing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Biomanufacturing Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Applikon Biotechnology BV, bbi-biotech GmbH, Biofluidica, Inc., Danaher Corporation, Eppendorf AG, ESCO Group, Eurofins Scientific SE, GEA Group AG, GENEWIZ, Inc. by Azenta Life Sciences, Hamilton Company, Illumina, Inc., Macrogen Inc., Merck KGaA, Oxford Nanopore Technologies plc, PBS Biotech, Inc., PerkinElmer Inc., QIAGEN N.V., Sartorius AG, Shanghai Bailun Biotechnology Co., Ltd., Solaris Biotechnology Srl by DONALDSON ITALIA S.R.L., Takara Bio Inc., Thermo Fisher Scientific Inc., ZETA GmbH, and Zymo Research Corporation.

Market Segmentation & Coverage

This research report categorizes the Next-Generation Biomanufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Continuous Upstream Biomanufacturing, Downstream Biomanufacturing, and Single-Use Upstream Biomanufacturing.
• Based on Application, market is studied across Hormones, Monoclonal Antibodies, Recombinant Proteins, and Vaccines.
• Based on End-User, market is studied across Biopharmaceutical Companies, Contract Manufacturing Organizations, and Research Institutions.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing demand for biopharmaceuticals and gene therapies
    • 5.1.1.2. Rising need to enhance flexibility and scalability of biomanufacturing
    • 5.1.1.3. Adoption of process automation and continuous manufacturing
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of next-generation biomanufacturing
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in next-generation biomanufacturing
    • 5.1.3.2. Significant investments in next-generation biomanufacturing
  • 5.1.4. Challenges
    • 5.1.4.1. Technical challenges in next-generation biomanufacturing
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Next-Generation Biomanufacturing Market, by Type

• 6.1. Introduction
• 6.2. Continuous Upstream Biomanufacturing
• 6.3. Downstream Biomanufacturing
• 6.4. Single-Use Upstream Biomanufacturing

7. Next-Generation Biomanufacturing Market, by Application

• 7.1. Introduction
• 7.2. Hormones
• 7.3. Monoclonal Antibodies
• 7.4. Recombinant Proteins
• 7.5. Vaccines

8. Next-Generation Biomanufacturing Market, by End-User

• 8.1. Introduction
• 8.2. Biopharmaceutical Companies
• 8.3. Contract Manufacturing Organizations
• 8.4. Research Institutions

9. Americas Next-Generation Biomanufacturing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Next-Generation Biomanufacturing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Next-Generation Biomanufacturing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Agilent Technologies, Inc.
• 2. Applikon Biotechnology BV
• 3. bbi-biotech GmbH
• 4. Biofluidica, Inc.
• 5. Danaher Corporation
• 6. Eppendorf AG
• 7. ESCO Group
• 8. Eurofins Scientific SE
• 9. GEA Group AG
• 10. GENEWIZ, Inc. by Azenta Life Sciences
• 11. Hamilton Company
• 12. Illumina, Inc.
• 13. Macrogen Inc.
• 14. Merck KGaA
• 15. Oxford Nanopore Technologies plc
• 16. PBS Biotech, Inc.
• 17. PerkinElmer Inc.
• 18. QIAGEN N.V.
• 19. Sartorius AG
• 20. Shanghai Bailun Biotechnology Co., Ltd.
• 21. Solaris Biotechnology Srl by DONALDSON ITALIA S.R.L.
• 22. Takara Bio Inc.
• 23. Thermo Fisher Scientific Inc.
• 24. ZETA GmbH
• 25. Zymo Research Corporation